Stock KYMR KYMERA THERAPEUTICS, INC.
Add to a list

Kymera Therapeutics, Inc. Share Price

Stocks

KYMR

US5015751044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 07:54:17 12/06/2026 pm IST 		5-day change 1st Jan Change
85.77 USD +3.39% Intraday chart for Kymera Therapeutics, Inc. +15.81% +10.33%
05:39pm Kymera Says KT-621 Data in Japanese Adults Comparable With Previous Studies MT
09/06 Kymera Therapeutics Unlocks $20 Million Milestone After Dosing First Participant in KT-485 Phase 1 Trial MT
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Kymera Therapeutics, Inc.

Market Cap 682.41Cr 592.19Cr 545.87Cr 511.49Cr 955.67Cr 65TCr 975.57Cr 6.51TCr 2.52TCr 31TCr 2.56TCr 2.51TCr 1,09500Cr P/E Ratio 2026 *
-23.4x
P/E Ratio 2027 * -19.1x
Enterprise Value 548.46Cr 475.95Cr 438.72Cr 411.08Cr 768.07Cr 53TCr 784.07Cr 5.23TCr 2.03TCr 25TCr 2.06TCr 2.01TCr 88TCr EV / Sales 2026 *
66.2x
EV / Sales 2027 * 144x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -
* Estimated data More valuation ratios

Chart: Kymera Therapeutics, Inc.

Dynamic Chart

Latest news : Kymera Therapeutics, Inc.

05:39pm Kymera Says KT-621 Data in Japanese Adults Comparable With Previous Studies MT
09/06 Kymera Therapeutics Unlocks $20 Million Milestone After Dosing First Participant in KT-485 Phase 1 Trial MT
09/06 Kymera Therapeutics, Inc. Announces Executive Changes CI
08/06 Kymera Therapeutics Presents New Preclinical Data for Kt-579, Oral Irf5 Degrader, At Eular and Focis Congresses CI
15/05 Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses RE
15/05 Kymera Therapeutics, Inc. Announces Presentations And Clinical Data For KT-621 Oral STAT6 Degrader CI
12/05 Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09:20 AM
06/05 Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target MT
05/05 Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week CI
30/04 Kymera Therapeutics, Inc., Q1 2026 Earnings Call, Apr 30, 2026
30/04 Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises MT
30/04 Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
30/04 Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss MT
More news

Last Transcript: Kymera Therapeutics, Inc.

Logo Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09:20 AM
12/05
More transcripts

Analysts' recommendations: Kymera Therapeutics, Inc.

06/05 Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target MT
03/03 UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating MT
22/12 B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating MT
16/12 Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says MT
16/12 RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk MT
More recommendations

Press Releases: Kymera Therapeutics, Inc.

04:31pm Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting AQ
09/06 Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration AQ
09/06 Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations AQ
08/06 Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses AQ
27/05 Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference AQ
More press releases

News in other languages: Kymera Therapeutics, Inc.

09/12 MÄRKTE USA/Anleger halten sich vor Zinsentscheid mit Käufen zurück
09/12 Voorzichtige weekstart op Wall Street
08/12 MÄRKTE USA/Vor Zinsentscheid macht sich Vorsicht breit
09/24/09 MÄRKTE USA/Erneute Rekorde - Powell-Aussagen setzen keinen Impuls
09/24/09 MÄRKTE USA/Rekordjagd geht weiter - Powell-Aussagen ohne Einfluss
More news

Quotes and Performance

1 day+3.44%
1 week+15.81%
Current month+5.44%
1 month+2.75%
3 months+10.77%
6 months-4.27%
Current year+10.33%
More quotes

Course Extremes

1 week 73.05
Extreme 73.05
 86.32
1 month 69.48
Extreme 69.48
 86.7
Current year 66.2
Extreme 66.205
 95.9
1 year 36.65
Extreme 36.65
 103
3 years 9.6
Extreme 9.6
 103
5 years 9.6
Extreme 9.6
 103
10 years 9.6
Extreme 9.6
 103
More quotes

Managers and Directors: Kymera Therapeutics, Inc.

Manager TitleAgeSince
Nello Mainolfi CEO
 Chief Executive Officer 47 01/11/2019
Bruce Jacobs DFI
 Director of Finance/CFO 56 15/07/2019
Vijay Sabesan CTO
 Chief Tech/Sci/R&D Officer 53 06/12/2021
Director TitleAgeSince
Bruce Booth CHM
 Chairman 51 01/08/2017
Nello Mainolfi BRD
 Director/Board Member 47 01/11/2019
Gorjan Hrustanovic BRD
 Director/Board Member 37 01/03/2020
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
02/06
Bruce Jacobs
Fiscal year

Chief Financial Officer

25,306 0.0308%
27/05
Jeremy Chadwick
Sell

Chief Operating Officer

-4,279 0.0052%
19/05
Pamela Esposito
Fiscal year

Director

2,000 0.0024%
Transaction History

Other Biotechnology & Medical Research

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
KYMERA THERAPEUTICS, INC. Stock Kymera Therapeutics, Inc.
+3.39%+15.81%+81.54%+241.49% 682.41Cr
LONZA GROUP AG Stock Lonza Group AG
-0.99%+0.84%-16.06%-12.83% 4.3TCr
REVOLUTION MEDICINES, INC. Stock Revolution Medicines, Inc.
+3.02%+3.26%+274.84%+508.83% 3.17TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.15%-1.77%+13.25%-14.96% 3.02TCr
BEONE MEDICINES AG Stock BeOne Medicines AG
+1.53%-2.36%-4.63%+23.70% 2.89TCr
CELLTRION, INC. Stock Celltrion, Inc.
-0.66%-5.84%+7.59%+12.76% 2.39TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
-0.57%+4.37%+55.96%+117.46% 1.36TCr
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
0.00%-0.86%+6.52%+8.06% 1.3TCr
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
+3.16%+5.64% - - 1.34TCr
IONIS PHARMACEUTICALS, INC. Stock Ionis Pharmaceuticals, Inc.
+0.16%-0.66%+107.72%+77.73% 1.22TCr
Average +0.81%-0.67%+58.52%+106.92% 2.17TCr
Weighted average by Cap. +0.54%-1.97%+55.06%+100.49%
See all sector performances

Financials

2026 *2027 *
Net sales 8.28Cr 7.19Cr 6.62Cr 6.21Cr 12Cr 792.91Cr 12Cr 79Cr 31Cr 382.21Cr 31Cr 30Cr 1.33TCr 3.91Cr 3.4Cr 3.13Cr 2.93Cr 5.48Cr 374.62Cr 5.59Cr 37Cr 14Cr 180.58Cr 15Cr 14Cr 627.88Cr
Net income -34Cr -30Cr -27Cr -26Cr -48Cr -3.27TCr -49Cr -325.64Cr -126.08Cr -1.58TCr -128.11Cr -125.35Cr -5.48TCr -44Cr -38Cr -35Cr -33Cr -61Cr -4.18TCr -62Cr -416.32Cr -161.19Cr -2.01TCr -163.79Cr -160.26Cr -7TCr
Net Debt -133.95Cr -116.24Cr -107.15Cr -100.4Cr -187.59Cr -13TCr -191.5Cr -1.28TCr -494.88Cr -6.18TCr -502.86Cr -492.02Cr -21TCr -120.4Cr -104.48Cr -96Cr -90Cr -168.61Cr -12TCr -172.12Cr -1.15TCr -444.79Cr -5.56TCr -451.97Cr -442.23Cr -19TCr
* Estimated data More financial data

Company Profile

Logo Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.
Employees
253
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
12/26/12 86.03 $ +3.70% 53,238
11/26/11 82.96 $ +6.05% 6,74,524
10/26/10 78.23 $ +1.72% 6,04,784
09/26/09 76.91 $ +4.00% 7,48,279
08/26/08 73.95 $ -0.24% 4,53,743

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

-
ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

BBB
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
82.96USD
Average target price
119.43USD
Spread / Average Target
+43.96%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. KYMR Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition